Cód QR

Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review

Abstract Recent advances in multiple myeloma (MM) treatment, including bispecific antibodies (BsAbs), have improved outcomes. Elranatamab, a BsAb targeting B-cell maturation antigen and CD3, has shown efficacy in relapsed/refractory MM (RRMM). However, its use in patients with end-stage renal diseas...

Cur síos iomlán

Sábháilte in:
Príomhchruthaitheoirí: Daisuke Ogiya, Rikio Suzuki, Shun Goto, Yosuke Nakagawa, Miina Nasukawa, Shino Iwata, Hidetsugu Kawai, Masako Toyosaki, Shinichiro Machida, Makoto Onizuka, Yoshiaki Ogawa, Hiroshi Kawada
Formáid: Artigo
Teanga:Inglês
Foilsithe / Cruthaithe: Springer 2025-10-01
Sraith:Annals of Hematology
Ábhair:
Multiple myeloma
End-stage renal disease
Hemodialysis
Bispecific antibody
Elranatamab
Rochtain ar líne:https://doi.org/10.1007/s00277-025-06689-0
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla